Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Trial Profile

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abexinostat (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Malignant melanoma; Neuroendocrine carcinoma; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Apr 2020 Planned End Date changed from 15 Apr 2020 to 15 Apr 2022.
    • 01 Apr 2020 Planned primary completion date changed from 15 Feb 2020 to 15 Feb 2022.
    • 30 Aug 2019 According to a Xynomic Pharmaceuticals media release, the enrollment in the Dose Expansion portion of this trial is ongoing to ascertain the response rate and disease control rate across tumor types.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top